Douglas F. Kling - 02 Jan 2025 Form 4 Insider Report for NewAmsterdam Pharma Co N.V. (NAMS)

Role
Chief Operating Officer
Signature
/s/ Louise Kooij by Power of Attorney from Douglas F. Kling
Issuer symbol
NAMS
Transactions as of
02 Jan 2025
Net transactions value
$0
Form type
4
Filing time
06 Jan 2025, 17:57:08 UTC
Previous filing
03 Jan 2024
Next filing
07 Jan 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NAMS Option (right to buy) Award $0 +250,000 $0.000000 250,000 02 Jan 2025 Ordinary Shares 250,000 $25.96 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying the option will vest on January 2, 2026, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.